Akari Therapeutics, Plc
AKTX
$1.07
-$0.04-3.60%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 09/30/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -39.42% | -27.50% | 29.58% | -27.57% | -24.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.13% | 20.37% | 30.37% | -36.84% | -58.31% |
| Operating Income | 26.13% | -20.37% | -30.37% | 36.84% | 58.31% |
| Income Before Tax | -0.84% | -88.95% | -656.04% | -1.71% | 16.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.84% | -88.95% | -656.04% | -1.71% | 16.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -0.84% | -88.95% | -656.04% | -1.71% | 16.68% |
| EBIT | 26.13% | -20.37% | -30.37% | 36.84% | 58.31% |
| EBITDA | 26.10% | -20.39% | -30.11% | 36.85% | 58.32% |
| EPS Basic | 58.17% | -1.47% | -409.00% | 35.54% | 43.67% |
| Normalized Basic EPS | 73.70% | 23.95% | -408.96% | 35.54% | 43.68% |
| EPS Diluted | 58.17% | -1.47% | -413.09% | 35.54% | 43.67% |
| Normalized Diluted EPS | 73.70% | 23.95% | -413.08% | 35.54% | 43.68% |
| Average Basic Shares Outstanding | 141.04% | 86.22% | 79.99% | 57.79% | 47.94% |
| Average Diluted Shares Outstanding | 140.00% | 88.00% | 83.33% | 52.94% | 47.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
